These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24757049)

  • 1. A modest proposal for dropping poor arms in clinical trials.
    Proschan MA; Dodd LE
    Stat Med; 2014 Aug; 33(19):3241-52. PubMed ID: 24757049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Many-to-one comparisons after safety selection in multi-arm clinical trials.
    Hlavin G; Hampson LV; Koenig F
    PLoS One; 2017; 12(6):e0180131. PubMed ID: 28651023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled multi-arm platform design using predictive probability.
    Hobbs BP; Chen N; Lee JJ
    Stat Methods Med Res; 2018 Jan; 27(1):65-78. PubMed ID: 26763586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.
    Carreras M; Brannath W
    Stat Med; 2013 May; 32(10):1677-90. PubMed ID: 22744936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New designs for the selection of treatments to be tested in randomized clinical trials.
    Simon R; Thall PF; Ellenberg SS
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
    Bratton DJ; Phillips PP; Parmar MK
    BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible sequential designs for multi-arm clinical trials.
    Magirr D; Stallard N; Jaki T
    Stat Med; 2014 Aug; 33(19):3269-79. PubMed ID: 24825588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A varying-stage adaptive phase II/III clinical trial design.
    Dong G
    Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim treatment selection with a flexible selection margin in clinical trials.
    Wu Y; Zhao PL
    Stat Med; 2013 Jul; 32(15):2529-43. PubMed ID: 23212767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding experimental treatment arms to multi-arm multi-stage platform trials in progress.
    Burnett T; König F; Jaki T
    Stat Med; 2024 Aug; 43(18):3447-3462. PubMed ID: 38852991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-sample proportion testing procedures for hypothesis of inequality.
    Zhong W; Zhong B
    J Biopharm Stat; 2013 May; 23(3):604-17. PubMed ID: 23611198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of methods for constructing confidence intervals after phase II/III clinical trials.
    Kimani PK; Todd S; Stallard N
    Biom J; 2014 Jan; 56(1):107-28. PubMed ID: 24173686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graphical search for two-stage designs for phase II clinical trials.
    Jung SH; Carey M; Kim KM
    Control Clin Trials; 2001 Aug; 22(4):367-72. PubMed ID: 11514038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified varying-stage adaptive phase II/III clinical trial design.
    Dong G; Vandemeulebroecke M
    Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.